Veteran healthcare and consumer technology operator turned investor with experience scaling growth-stage companies and advising boards on commercial strategy and go-to-market execution. Jane Bortnem has led marketing and product functions at venture-backed startups and served as an executive-in-residence and angel investor, focusing on customer acquisition, retention economics and category expansion. Market relevance centers on growth equity and early-stage rounds where operational playbooks and customer-driven scaling drive valuation upside.
Veteran healthcare and consumer technology operator turned investor with experience scaling growth-stage companies and advising boards on commercial strategy and go-to-market execution. Jane Bortnem has led marketing and product functions at venture-backed startups and served as an executive-in-residence and angel investor, focusing on customer acquisition, retention economics and category expansion. Market relevance centers on growth equity and early-stage rounds where operational playbooks and customer-driven scaling drive valuation upside.
Focuses on growth-stage healthcare and consumer technology companies where operator-led capital accelerates customer acquisition and retention-driven revenue. Prefers early growth equity and seed rounds, underwriting opportunities through unit-economics, payback period and category expansion potential. Deploys smaller, active checks coupled with board or advisor roles to drive go-to-market execution, product-market fit and scalable acquisition channels. Time horizon is multi-year, value creation through commercial scaling and disciplined follow-on allocation to protect ownership and upside.
Focuses on growth-stage healthcare and consumer technology companies where operator-led capital accelerates customer acquisition and retention-driven revenue. Prefers early growth equity and seed rounds, underwriting opportunities through unit-economics, payback period and category expansion potential. Deploys smaller, active checks coupled with board or advisor roles to drive go-to-market execution, product-market fit and scalable acquisition channels. Time horizon is multi-year, value creation through commercial scaling and disciplined follow-on allocation to protect ownership and upside.
| Trades 3211 | Longs Won 2319/3211 72% | Profit Factor 23.97 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $320,573.93 |
| Average Win $55,669.07 | Best Trade (Aug 17) $7.55M | Sharpe Ratio -11.24 |
| Average Loss -$6,037.05 | Worst Trade (Aug 02) -$2.95M | Z-Score 17.47 (100%) |
| Commissions $0 | Avg. Trade Length 1y 7m 3w 6d | Expectancy $38,527.42 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 83,333 | 75,000 | 66,667 | 58,333 | 50,000 | 41,667 | 33,333 | 25,000 | 16,667 | 8,333 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 13,096 | $2.57M | $4.05M | - | $1.47M | 57.17% | -7.354% |
AAXJ iShares MSCI All Country Asia ex Japan ETF | 1,933 | $128,450.56 | $214,021.76 | - | $85,571.2 | 66.62% | +0.801% |
ABBV AbbVie Inc. | 208 | $34,485.32 | $52,195.52 | - | $17,710.2 | 51.36% | -2.513% |
ABT Abbott Laboratories | 2,005 | $247,414.09 | $211,928.5 | - | -$35,485.59 | -14.34% | +0.085% |
ACN Accenture plc Class A | 253 | $68,725.29 | $41,977.76 | - | -$26,747.53 | -38.92% | +1.611% |
ACWI iShares MSCI ACWI ETF | 68 | $6,524.47 | $10,637.24 | - | $4,112.77 | 63.04% | +0.495% |
ADAM Adamas Trust, Inc. | 6 | $60 | $54.42 | - | -$5.58 | -9.3% | +1.454% |
ADI Analog Devices, Inc. | 52 | $10,130.16 | $19,105.32 | - | $8,975.16 | 88.6% | +0.202% |
ADP Automatic Data Processing Inc. | 454 | $100,900.12 | $120,972.84 | - | $20,072.72 | 19.89% | +0.982% |
AFK VanEck Vectors Africa Index ETF | 462 | $11,259 | $12,072.06 | - | $813.06 | 7.22% | +0.153% |
AFL Aflac Inc. | 76 | $8,451 | $9,688.48 | - | $1,237.48 | 14.64% | +0.094% |
AGG iShares Core U.S. Aggregate Bond ETF | 22,186 | $2.18M | $2.16M | - | -$15,034.5 | -0.69% | -0.256% |
AGZD WisdomTree Trust | 3,234 | $71,536.08 | $73,120.74 | - | $1,584.66 | 2.22% | +0.222% |
AIG American International Group Inc. | 10 | $547 | $785.8 | - | $238.8 | 43.66% | -0.393% |
AIRR First Trust RBA American Industrial Renaissance ETF | 345 | $21,344.74 | $40,382.25 | - | $19,037.51 | 89.19% | +1.588% |
ALRS Alerus Financial Corporation | 830 | $15,365.04 | $27,614.1 | - | $12,249.06 | 79.72% | -0.864% |
ALSN Allison Transmission Holdings Inc. | 34 | $3,253 | $3,894.36 | - | $641.36 | 19.72% | -0.78% |
AMAT Applied Materials, Inc. | 264 | $38,419.25 | $134,024.88 | - | $95,605.63 | 248.85% | +1.176% |
AMD Advanced Micro Devices, Inc. | 235 | $49,991.6 | $111,895.25 | - | $61,903.65 | 123.83% | -1.904% |
AME Ametek Inc. | 42 | $6,739.89 | $10,151.82 | - | $3,411.93 | 50.62% | +0.708% |